To evaluate the safety and efficacy of Deep Brain Stimulation for patients with MDD, who have failed to respond to at least 4 treatments in the current episode. The primary outcome assessment will occur at 6 months and all patients will be followed-up for 1 year.
The study will compare group 1 who will be implanted with the device and activated for stimulation and group 2 (the control group) who will be implanted with the device but will not receive active stimulation for the first six months of the study. This study will also aim to describe the effects of DBS on measures of regional brain metabolic activity using electroencephalography (EEG) and PET (positron emission tomography) scanning.
The study is ongoing.
More details can be found on the BROADEN Study website (external link).
Professor Keith Matthews
This study will use Diffusion Tensor Imaging (DTI) and functional magnetic resonance imaging (fMRI) to relate neuropsychological performance and clinical status (symptoms) with measures of white matter integrity and grey matter function in 'emotional-processing-relevant' brain networks. This will lead to a greater understanding of the consequences and side-effects of neurosurgery. Using DTI in addition to fMRI will help to map lesion topography and subsequent effects on communicating white matter tracts with great precision, helping to develop our understanding of the functional architecture of depression. This will help guide the development of novel and more effective treatment strategies.
Professor Douglas Steele
The overarching study aim is to establish the potential of deep brain stimulation (DBS) for people with obsessive compulsive disorder (OCD) who have failed to respond to the best currently available medical treatment and who are significantly disabled by their symptoms. Previous studies indicate that DBS of the ventral striatum/ventral capsule (VS/VC) and the subthalamic nucleus (STN) are effective for OCD. About two-thirds showed clear improvement but remained moderately symptomatic. The main objective of this study is to investigate whether this efficacy can be improved by determining:
i. Whether DBS at both sites is more efficacious than DBS at either site alone for the alleviation of all symptom dimensions of OCD;
ii. The different mechanisms of action of DBS at the two brain sites which explain why DBS at both sites is better than each site alone;
iii. Whether adjunctive cognitive behavioural therapy improves DBS-mediated clinical outcomes.
Professor Eileen Joyce, UCL, London